Avigen’s Argument With Largest Shareholder Emblematic Of Biotech Troubles
This article was originally published in The Pink Sheet Daily
Executive Summary
Biotechnology Value Fund wants the firm to accept a merger offer from MediciNova; Avigen wants more time to keep rolling the dice.
You may also be interested in...
MediciNova and Avigen Move One Step Closer To A Merger
Two months after unveiling a tentative framework for a merger, MediciNova and Avigen hammer out an agreement that gives MediciNova ownership of Avigen's remaining assets for a song.
MediciNova and Avigen Move One Step Closer To A Merger
Two months after unveiling a tentative framework for a merger, MediciNova and Avigen hammer out an agreement that gives MediciNova ownership of Avigen's remaining assets for a song.
Avigen Board Survives Proxy Fight But Company Will Liquidate Holdings
In abandoning its efforts to find a buyer, troubled biotech promises shareholders a return of at least $1.20 per share.